胶质母细胞瘤中性别偏向性坏死性炎症被揭示为贝伐珠单抗获益的预测因素
这项回顾性研究按性别分层分析胶质母细胞瘤(GBM)的血管与免疫特征,发现缺氧条件下存在两种与性别差异相关的肿瘤免疫血管生态系统,其中男性低ESR1表达亚组表现为坏死性炎症肿瘤,富含髓源性抑制细胞;基于此分层可识别可能从贝伐珠单抗(BVZ)获益的患者,并发现可用于预测BVZ最大获益人群的遗传特征。
要点
- GBM男性发病率及生存预后差于女性,本研究按性别分层探讨其肿瘤生物学差异。
- 男性低ESR1表达亚组呈坏死性炎症表型,与髓源性抑制细胞浸润相关。
- 基于该性别差异分层可识别可能对贝伐珠单抗治疗有反应的患者群体。
核心结论
- 本研究提出基于GBM性别差异的分层,将不良预后与坏死区域免疫抑制性髓系细胞的存在相关联。
- 该分层可能改变当前GBM的预后判断,并识别对BVZ治疗有反应的患者。
研究设计与样本
- 回顾性研究,GBM患者按性别分层。
- 采用免疫组织化学、RNA测序和RT-qPCR分析73个肿瘤的血管与免疫特征差异。
- 使用转录组分析、基因集富集分析和通路富集分析发现各组优势分子通路。
- 在另一回顾性GBM队列(36个肿瘤)中基于性别差异研究贝伐珠单抗(VEGFA阻断抗体)的治疗效果。
主要发现
- 缺氧肿瘤条件下形成两种与性别差异相关的肿瘤免疫血管生态系统,并涉及ESR1表达。
- 男性低ESR1表达亚组以血管脆性为特征,伴坏死区域和高炎症(称为坏死性炎症肿瘤)。
- 该男性特异性肿瘤亚型的高炎症与髓源性抑制细胞浸润相关。
- 利用该分层识别出可能对贝伐珠单抗有反应的患者组,并发现可能作为BVZ最大获益预测因素的遗传特征。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma (GBM) is a highly malignant brain tumor that affects men more often than women. In addition, the former shows a poorer survival prognosis. To date, the reason for this sex-specific aggressiveness remains unclear. Therefore, the aim of this study is to investigate tumor processes that explain these sex differences. METHODS: This was a retrospective study of GBM patients which was stratified according to sex. A cohort with 73 tumors was analyzed with immunohistochemistry, RNA-seq and RT-qPCR to characterize differences in vascular and immunological profiles. Transcriptomic profiling, gene set enrichment analysis, and pathway enrichment analysis were used for discovering molecular pathways predominant in each group. We further investigated the therapeutic effect of bevacizumab (vascular endothelial growth factor A (VEGFA) blocking antibody) in a retrospective GBM cohort (36 tumors) based on sex differences. RESULTS: We found that under hypoxic tumor conditions, 2 distinct tumor immuno-angiogenic ecosystems develop linked to sex differences and ESR1 expression is generated. One of these subgroups, which includes male patients with low ESR1 expression, is characterized by vascular fragility associated with the appearance of regions of necrosis and high inflammation (called necroinflamed tumors). This male-specific tumor subtype shows high inflammation related to myeloid-derived suppressor cells infiltration. Using this stratification, we identified a possible group of patients who could respond to bevacizumab (BVZ) and revealed a genetic signature that may find clinical applications as a predictor of those who may benefit most from this treatment. CONCLUSIONS: This study provides a stratification based on the sexual differences in GBM, which associates the poor prognosis with the presence of immunosuppressive myeloid cells in the necrotic areas. This new stratification could change the current prognosis of GBM and identifies those who respond to BVZ treatment.
引用
- Hiller-Vallina S, Mondejar-Ruescas L, Caamaño-Moreno M, et al. Sexual-biased necroinflammation is revealed as a predictor of bevacizumab benefit in glioblastoma. Neuro Oncol. 2024. PMID: 38411438. doi:10.1093/neuonc/noae033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。